Kaufman Rossin Wealth LLC Invests $351,000 in Alnylam Pharmaceuticals, Inc. $ALNY

Kaufman Rossin Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 1,300 shares of the biopharmaceutical company’s stock, valued at approximately $351,000.

Several other institutional investors have also recently bought and sold shares of ALNY. Whipplewood Advisors LLC grew its stake in shares of Alnylam Pharmaceuticals by 208.8% during the 1st quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 71 shares in the last quarter. Bessemer Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 69 shares in the last quarter. Park Square Financial Group LLC acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth $28,000. Colonial Trust Co SC bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at $35,000. Finally, Washington Trust Advisors Inc. increased its stake in Alnylam Pharmaceuticals by 53.5% in the 1st quarter. Washington Trust Advisors Inc. now owns 175 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 61 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ALNY. Needham & Company LLC increased their price objective on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research note on Thursday, July 31st. JPMorgan Chase & Co. upped their target price on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an “overweight” rating in a report on Wednesday, August 6th. Chardan Capital raised their price target on Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a “buy” rating in a research note on Friday, August 1st. HC Wainwright boosted their price target on Alnylam Pharmaceuticals from $500.00 to $570.00 and gave the stock a “buy” rating in a research report on Thursday, August 7th. Finally, BMO Capital Markets increased their price objective on Alnylam Pharmaceuticals from $300.00 to $360.00 and gave the company an “outperform” rating in a report on Tuesday, June 24th. Twenty-two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $405.33.

Insiders Place Their Bets

In related news, Director Dennis A. Ausiello sold 31,448 shares of the firm’s stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $436.58, for a total transaction of $13,729,567.84. Following the transaction, the director directly owned 911 shares of the company’s stock, valued at approximately $397,724.38. This trade represents a 97.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jeffrey V. Poulton sold 2,274 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $1,030,735.98. Following the transaction, the executive vice president directly owned 50,121 shares in the company, valued at $22,718,345.67. This represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 108,531 shares of company stock valued at $41,087,238 in the last three months. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $458.31 on Thursday. The company has a 50-day simple moving average of $354.46 and a 200 day simple moving average of $294.11. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The company has a market capitalization of $60.08 billion, a price-to-earnings ratio of -185.55 and a beta of 0.25. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $466.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. The company had revenue of $773,689 billion for the quarter, compared to the consensus estimate of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm’s revenue for the quarter was up 17.3% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.